SSR3

Across TCGA pan-cancer cohorts, SSR3 mass-spec protein is linked to patient survival in 3 of 34 cancer types, making it a survival-associated SSR3 data layer compared with 26 for mass-spec protein and 3 for mutation status.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where higher SSR3 mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated SSR3 expression acts as an unfavorable survival marker, although some lineages such as HNSC show a favorable association.

CCRCC, HNSC, and LSCC are the cancer types where SSR3 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CCRCC	DFS	Median	III,IV	0.105	0.928	.003	38	view →
HNSC	DFS	Median	II,III,IV	0.870	0.675	.003	34	view →
LSCC	DFS	Median	II,III,IV	0.536	0.826	.011	4	view →

Pink = unfavorable, green = favorable. Showing the 3 strongest of 3 lineages.

SSR3–CCRCC (DFS)

Open the CCRCC breakdown →